Pancreatic Cancer Research

Journal articleBioorg Chem2019

Arylboronate prodrugs of doxorubicin as promising chemotherapy for pancreatic cancer.

Journal
Bioorg Chem
Published
24 July 2019
Citations
30
Type
Article

These are the paper’s bibliographic details. A summary of its population, design, endpoints and findings, each tied to a quote, has not been written for this paper yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

abstract license unknown

This study describes the synthesis of arylboronate-based ROS-responsive prodrugs of doxorubicin and their biological evaluation as anticancer agents. The determination of the most sensitive cancer type toward arylboronate prodrugs is crucial for further consideration of these molecules in clinical phase. … Excerpt only: this text is the publisher’s. Read it in full at the source.